--- title: "ClearPoint Neuro, Inc. (CLPT.US)" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/CLPT.US.md" symbol: "CLPT.US" name: "ClearPoint Neuro, Inc." industry: "Health Care Equipment" datetime: "2026-06-19T11:10:23.351Z" locales: - [en](https://longbridge.com/en/quote/CLPT.US.md) - [zh-CN](https://longbridge.com/zh-CN/quote/CLPT.US.md) - [zh-HK](https://longbridge.com/zh-HK/quote/CLPT.US.md) --- # ClearPoint Neuro, Inc. (CLPT.US) ## Company Overview ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula. It also provides ClearPoint software, which guides the physician in surgical planning, device alignment, navigation to the target, and procedure monitoring; ClearPoint Prism Neuro laser therapy system to necrotize or coagulate soft tissue; and IRRAflow system, an active fluid exchange platform. In addition, the company offers consulting services to its pharmaceutical and other medical technology partners, such as benchtop testing, preclinical studies, clinical trial support, regulatory consultation, and translation from the preclinical to the clinical setting. | Item | Detail | |------|--------| | Industry | Health Care Equipment | | Exchange | US Market | | Website | [www.clearpointneuro.com](https://www.clearpointneuro.com) | ## Key Drivers > *AI-analyzed key factors driving this stock's performance* ## Longbridge Financial Score™: C > *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge* > Updated: 2026-06-19T04:30:14.000Z **Overall: C (0.52)** **Industry**: Health Care Equipment | Metric | Value | |--------|-------| | Industry Ranking | 71 / 184 | | Industry Median | C | | Industry Average | C | - **Style**: Growth - Stocks whose main business is in the growth stage. - **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns. **Multi Score**: C #### Style Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | 25.99% | | | Net Profit YoY | -39.78% | | | P/B Ratio | 28.28 | | | Dividend Ratio | 0.00% | | #### Size Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 532914534.51 | | | Revenue | 40614000.00 | | #### Multi Score Score: C | Indicator | Value | Rating | |-----------|-------|--------| | ROE | -149.72% | E | | Profit Margin | -71.57% | E | | Gross Margin | 63.95% | A | | Revenue YoY | 25.99% | A | | Net Profit YoY | -39.78% | D | | Total Assets YoY | 210.66% | A | | Net Assets YoY | -5.73% | D | | Cash Flow Margin | 88.49% | C | | OCF YoY | 25.99% | A | | Turnover | 0.66 | B | | Gearing Ratio | 79.83% | E | ```chart-data:radar { "title": "Longbridge Financial Score - ClearPoint Neuro, Inc.", "chart_type": "radar", "dimensions": [ { "name": "Style Score", "grade": "", "indicators": [ { "name": "Revenue YoY", "value": "25.99%", "rating": "" }, { "name": "Net Profit YoY", "value": "-39.78%", "rating": "" }, { "name": "P/B Ratio", "value": "28.28", "rating": "" }, { "name": "Dividend Ratio", "value": "0.00%", "rating": "" } ] }, { "name": "Size Score", "grade": "", "indicators": [ { "name": "Market Cap", "value": "532914534.51", "rating": "" }, { "name": "Revenue", "value": "40614000.00", "rating": "" } ] }, { "name": "Multi Score", "grade": "C", "indicators": [ { "name": "ROE", "value": "-149.72%", "rating": "E" }, { "name": "Profit Margin", "value": "-71.57%", "rating": "E" }, { "name": "Gross Margin", "value": "63.95%", "rating": "A" }, { "name": "Revenue YoY", "value": "25.99%", "rating": "A" }, { "name": "Net Profit YoY", "value": "-39.78%", "rating": "D" }, { "name": "Total Assets YoY", "value": "210.66%", "rating": "A" }, { "name": "Net Assets YoY", "value": "-5.73%", "rating": "D" }, { "name": "Cash Flow Margin", "value": "88.49%", "rating": "C" }, { "name": "OCF YoY", "value": "25.99%", "rating": "A" }, { "name": "Turnover", "value": "0.66", "rating": "B" }, { "name": "Gearing Ratio", "value": "79.83%", "rating": "E" } ] } ] } ``` ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | -18.33 | 149/184 | - | - | - | | PB | 28.28 | 137/184 | 27.04 | 20.52 | 15.08 | | PS (TTM) | 13.12 | 114/184 | 12.61 | 10.22 | 8.91 | | Dividend Yield | 0.00% | - | - | - | - | ## Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | | --- | --- | --- | --- | --- | --- | --- | --- | | 01 | Delcath (DCTH.US) | C | A | B | A | A | A | | 02 | Electromed (ELMD.US) | A | B | A | A | B | A | | 03 | Intuitive Surgical (ISRG.US) | A | B | C | A | B | B | | 04 | Stryker (SYK.US) | A | C | C | C | B | B | | 05 | Boston Scientific (BSX.US) | A | B | C | C | B | B | ## Institutional View ### Analyst Rating Distribution > As of 2026-06-18T04:00:00.000Z Total Analysts: **3** | Rating | Count | Percentage | |--------|-------|-----------| | Buy | 3 | 100% | ### Target Price Forecast | Metric | Price | |--------|-------| | Current Price | 17.77 | | Highest Target | 30.00 | | Lowest Target | 16.00 | ## References - [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/CLPT.US/overview.md) - [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/CLPT.US/norm.md) - [Related News](https://longbridge.com/en/quote/CLPT.US/news.md) - [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/CLPT.US/filings.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**